89581-41-9

Upstream product

• 89465-98-5 4-bromo-2-nitrobenzene-1-sulfonyl chloride 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 875-51-4 4-Bromo-2-nitroaniline 

Downstream Products

• 54734-81-5 2-amino-4-bromo-benzenesulfonamide 
• 1357259-43-8 C₁₉H₁₈BrN₃O₄S 
• 1357259-44-9 C₄₃H₄₅N₇O₇S 
• 1357259-46-1 C₄₈H₅₄N₈O₈S 
• 1357258-67-3 C₄₅H₄₈N₈O₈S 
• 1446139-35-0 C₄₄H₅₂N₈O₈S 
• 1446139-34-9 C₄₃H₄₄N₆O₆S 
• 1612855-02-3 C₅₀H₆₁N₉O₈S 
• 1612853-95-8 C₅₁H₆₂N₈O₈S 
• 1560648-26-1 C₁₉H₁₈BrN₃O₄S 

Relevant academic research and scientific papers

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula I, including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.

IMIDAZOLYL-SUBSTITUTED AZABENZOPHENONE COMPOUNDS

The compounds of formula (I) in which X, Y, R1 and R2 have the meanings as given in the description are novel effective inhibitors of the inducible nitric oxide synthase.

IMIDAZOLYL-SUBSTITUTED DIAZABENZOPHENONE COMPOUNDS

The compounds of formula (I) in which X, Y, R1 and R2 have the meanings as given in the description are novel effective inhibitors of the inducible nitric oxide synthase.